Dr Daniel Barratt

Int Grant-Funded Researcher B

School of Biomedicine

Faculty of Health and Medical Sciences

Eligible to supervise Masters and PhD - email supervisor to discuss availability.

Dr Daniel Barratt is a mid career researcher in the Neuroimmunopharmacology Lab of Prof Mark Hutchinson (Discipline of Physiology) and member of the Clinical Pharmacogenomics and Drug Disposition Lab in the Discipline of Pharmacology. He is also a member of the ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP).

Dr Barratt has over 15 years of research experience in the area called "pharmacogenomics"; determining how our genes influence our individual responses to drugs, and how this can be used to better personalise treatments for improved safety and efficacy.

My Research
Career
Publications
Teaching
Supervision
Professional Activities
Contact

My current research focuses on identifying predictors and biomarkers of acute and chronic pain, analgesic response, and physical and psychological performance and resilience, in humans and livestock.

I have an extensive research background in clinical pharmacogenomics (especially opioid analgesics) and the neuroimmunogenetics of pain. In addition, I have led research integrating clinical and experimental pharmacokinetics, pharmacogenomics and drug resistance markers, for the personalised dosing of tyrosine kinase inhibitors against cancer. I have also been working collaboratively to identify common drug-related genetic variants in Aboriginal Australians to guide recommendations for personalised prescribing, on clinical pharmacology and pharmacogenetics research to guide precision medicine approaches in organ transplant, and on the clinical pharmacokinetics and pharmacogenetics of infectious disease treatments in Papua New Guinea.

Current Research Projects

"Biomarkers of persistent pain in livestock": Translating human biomarkers of pain into the livestock setting to predict the chronic pain of animal husbandry practices.
“A novel pathway to reduce the burden of chronic pain”: Determining how neuroimmune signalling pathway (NSP) (epi)genetics influence chronic postsurgical pain and establishing an improved framework for developing personalised pain treatment based on NSP biomarkers.
“Biomarker determinants of ketamine efficacy”: Determining pharmacokinetic and genomic determinants of ketamine efficacy in chronic pain and treatment-resistant depression.
“Improving the treatment of breathlessness”: Determining genetic predictors of the efficacy of sustained-release morphine in chronic refractory breathlessness.
“Personalised medicines for Aboriginal people”: Identifying and comparing drug-related genetic variation in Aboriginal and non-Aboriginal Australians, to ultimately guide personalised prescribing in Aboriginal people.
“Pharmacogenomics of mercaptopurine toxicity among paediatric ALL patients”: Determining the relationship between NUDT15 genetic deficiency and thiopurine toxicity in Aboriginal children with acute lymphoblastic leukaemia and lymphoma, and establishing a NUDT15 sequencing protocol for clinical implementation.
“Clinical pharmacology of infectious disease treatments in Papua New Guinea”: Identifying pharmacokinetic and genomic determinants of treatment response to enable drug therapy optimization for the PNG population.
“The inside story on variable tyrosine kinase inhibitor response and toxicity”: Integrating clinical and experimental pharmacokinetics, pharmacogenomics and mechanisms of drug resistance, for the personalised dosing of tyrosine kinase inhibitors (TKI).

Appointments

Date	Position	Institution name
2020 - 2023	Internal Grant-Funded Researcher B	University of Adelaide
2015 - 2019	NHMRC Postdoctoral Research Officer	University of Adelaide
2011 - 2014	Research Assistant	University of Adelaide

Education

Date Institution name Country Title

University of Adelaide Australia PhD

University of Adelaide Australia BSc (Hons)
Research Interests

Biomarkers Clinical Pharmacology and Therapeutics Pain Pharmacogenomics Cancer Biology and Clinical Oncology Immunology and Infection Musculoskeletal Health Neuroscience, Behaviour and Brain Health Surgical and Health Systems Innovation

Date	Institution name	Country	Title
	University of Adelaide	Australia	PhD
	University of Adelaide	Australia	BSc (Hons)

Journals

Year	Citation
2024	Lacagnina, M. J., Willcox, K. F., Boukelmoune, N., Bavencoffe, A., Sankaranarayanan, I., Barratt, D. T., . . . Grace, P. M. (2024). B cells drive neuropathic pain-related behaviors in mice through IgG-Fc gamma receptor signaling. Science translational medicine, 16(766), eadj1277. DOI Scopus1
2024	Barratt, D. T., Klepstad, P., Dale, O., Kaasa, S., & Somogyi, A. A. (2024). Pharmacokinetic and neuroimmune pharmacogenetic impacts on slow-release morphine cancer pain control and adverse effects.. The Pharmacogenomics Journal, 24(3), 18-1-18-8. DOI
2022	Somogyi, A. A., Musolino, S. T., & Barratt, D. T. (2022). New pharmacological perspectives and therapeutic options for opioids: Differences matter. Anaesthesia and Intensive Care, 50(1-2), 127-140. DOI Scopus5 WoS3 Europe PMC3
2022	Abuhelwa, A. Y., Somogyi, A. A., Loo, C. K., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022). Population pharmacokinetics and pharmacodynamics of the therapeutic and adverse effects of ketamine in patients with treatment-refractory depression.. Clin Pharmacol Ther, 112(3), 720-729. DOI Scopus6 WoS3 Europe PMC5
2022	Kluger, M. T., Rice, D. A., Borotkanics, R., Lewis, G. N., Somogyi, A. A., Barratt, D. T., . . . McNair, P. J. (2022). Factors associated with persistent opioid use 6-12 months after primary total knee arthroplasty.. Anaesthesia, 77(8), 882-891. DOI Scopus8 WoS2 Europe PMC3
2021	Sallustio, B. C., Noll, B. D., Hu, R., Barratt, D. T., Tuke, S. J., Coller, J. K., . . . Somogyi, A. A. (2021). Tacrolimus dose, blood concentrations and acute nephrotoxicity, but not CYP3A5/ABCB1 genetics, are associated with allograft tacrolimus concentrations in renal transplant recipients. British Journal of Clinical Pharmacology, 87(10), 3901-3909. DOI Scopus18 WoS12 Europe PMC11
2021	Barratt, D. T., Sia, A. T., Tan, E. -C., & Somogyi, A. A. (2021). Innate immune and neuronal genetic markers are highly predictive of postoperative pain and morphine patient-controlled analgesia requirements in Indian but not Chinese or Malay hysterectomy patients. Pain Medicine, 22(11), 2648-2660. DOI Scopus5 WoS2 Europe PMC3
2021	Bordin Andriguetti, N., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2021). Instability of Efavirenz Metabolites Identified During Method Development and Validation. J Pharm Sci, 110(10), 3362-3366. DOI Scopus4 Europe PMC1
2021	Bordin Andriguetti, N., Van Schalkwyk, H. K., Barratt, D. T., Tucci, J., Pumuye, P., & Somogyi, A. A. (2021). Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele. Clinical and Translational Science, 14(6), 2521-2531. DOI Scopus7 WoS4 Europe PMC4
2020	Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2020). No major effect of innate immune genetics on acute kidney rejection in the first 2 weeks post-transplantation. Frontiers in Pharmacology, 10, 1686-1-1686-8. DOI Scopus3 WoS5 Europe PMC1
2019	Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation. Pharmacogenetics and Genomics, 29(1), 9-17. DOI Scopus8 WoS7 Europe PMC4
2019	Somogyi, A. A., Barratt, D. T., Phillips, E. J., Moore, K., Ilyas, F., & Gabb, G. M. (2019). High and variable population prevalence of HLA-B56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms. British Journal of Clinical Pharmacology*, 85(9), 2163-2169. DOI Scopus21 WoS17 Europe PMC11
2019	Hu, R., Barratt, D. T., Coller, J. K., Sallustio, B. C., & Somogyi, A. A. (2019). Is there a temporal relationship between trough whole blood tacrolimus concentration and acute rejection in the first 14 days after kidney transplantation?. Therapeutic Drug Monitoring, 41(4), 528-532. DOI Scopus6 WoS4 Europe PMC4
2018	Liu, J., Mustafa, S., Barratt, D., & Hutchinson, M. (2018). Corticosterone preexposure increases NF-κB translocation and sensitizes IL-1β responses in BV2 microglia-like cells. Frontiers in Immunology, 9(JAN), 1-12. DOI Scopus20 WoS15 Europe PMC12
2018	Hu, R., Barratt, D., Coller, J., Sallustio, B., & Somogyi, A. (2018). CYP3A53 and ABCB1 61A>G significantly influence dose-adjusted trough blood tacrolimus concentrations in the first three months post-kidney transplantation. Basic and Clinical Pharmacology and Toxicology, 123*(3), 320-326. DOI Scopus28 WoS17 Europe PMC14
2018	Tucci, J., Pumuye, P., Helsby, N., Barratt, D., Pokeya, P., Hombhanje, F., & Somogyi, A. (2018). Pharmacogenomics in Papua New Guineans: Unique profiles and implications for enhancing drug efficacy while improving drug safety. Pharmacogenetics and Genomics, 28(6), 153-164. DOI Scopus7 WoS5 Europe PMC6
2018	Rice, D., Kluger, M., McNair, P., Lewis, G., Somogyi, A., Borotkanics, R., . . . Walker, M. (2018). Persistent postoperative pain after total knee arthroplasty: a prospective cohort study of potential risk factors. British Journal of Anaesthesia, 121(4), 804-812. DOI Scopus112 WoS85 Europe PMC50
2017	Barratt, D., & Somogyi, A. (2017). Role of pharmacogenetics in personalised imatinib dosing. Translational Cancer Research, 6(S10), 1541-1557. DOI Scopus15 WoS11
2017	Barratt, D., Cox, H., Menelaou, A., Yeung, D., White, D., Hughes, T., & Somogyi, A. (2017). CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients. Clinical Pharmacokinetics, 56(8), 977-985. DOI Scopus20 WoS17 Europe PMC13
2016	Somogyi, A., Sia, A., Tan, E., Coller, J., Hutchinson, M., & Barratt, D. (2016). Ethnicity-dependent influence of innate immune genetic markers on morphine PCA requirements and adverse effects in postoperative pain. Pain, 157(11), 2458-2466. DOI Scopus25 WoS18 Europe PMC11
2016	Khan, M., Barratt, D., & Somogyi, A. (2016). Impact of CYP2C8∗3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib. Xenobiotica, 46(3), 278-287. DOI Scopus17 WoS14 Europe PMC8
2015	Barratt, D., Klepstad, P., Dale, O., Kaasa, S., & Somogyi, A. (2015). Innate immune signalling genetics of pain, cognitive dysfunction and sickness symptoms in cancer pain patients treated with transdermal fentanyl. PLoS One, 10(9), e0137179-1-e0137179-13. DOI Scopus24 WoS19 Europe PMC9
2015	Somogyi, A., Coller, J., & Barratt, D. (2015). Pharmacogenetics of opioid response. Clinical Pharmacology and Therapeutics, 97(2), 125-127. DOI Scopus36 WoS23 Europe PMC20
2014	Barratt, D., Bandak, B., Klepstad, P., Dale, O., Kaasa, S., Christrup, L., . . . Somogyi, A. (2014). Genetic, pathological and physiological determinants of transdermal fentanyl pharmacokinetics in 620 cancer patients of the EPOS study. Pharmacogenetics and Genomics, 24(4), 185-194. DOI Scopus47 WoS35 Europe PMC29
2014	Somogyi, A., Barratt, D., Ali, R., & Coller, J. (2014). Pharmacogenomics of methadone maintenance treatment. Pharmacogenomics, 15(7), 1007-1027. DOI Scopus40 WoS34 Europe PMC28
2014	Mulholland, C., Somogyi, A., Barratt, D., Coller, J., Hutchinson, M., Jacobson, G., . . . Sleigh, J. (2014). Association of innate immune single-nucleotide polymorphisms with the electroencephalogram during desflurane general anaesthesia. Journal of Molecular Neuroscience, 52(4), 497-506. DOI Scopus16 WoS11 Europe PMC9
2012	Grace, P., Hurley, D., Barratt, D., Tsykin, A., Watkins, L., Rolan, P., & Hutchinson, M. (2012). Harnessing pain heterogeneity and RNA transcriptome to idenitfy blood-based pain biomarkers: a novel correlational study design and bioinformatics approach in a graded chronic construction injury model. Journal of Neurochemistry, 122(5), 976-994. DOI Scopus23 WoS22 Europe PMC16
2012	Barratt, D., Coller, J., Hallinan, R., Byrne, A., White, J., Foster, D., & Somogyi, A. (2012). ABCB1 haplotype and OPRM1 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics. Pharmacogenomics and Personalized Medicine, 5(1), 53-62. DOI Scopus47 WoS42 Europe PMC25
2008	Coller, J., Barratt, D., & Somogyi, A. (2008). Response to "No influence of ABCB1 haplotypes on methadone dosage requirement". Clinical Pharmacology & Therapeutics, 83(5), 669-670. DOI Scopus3 WoS2
2007	Somogyi, A., Barratt, D., & Coller, J. (2007). Pharmacogenetics of opioids. Clinical Pharmacology & Therapeutics, 81(3), 429-444. DOI Scopus292 WoS240 Europe PMC168
2006	Coller, J., Barratt, D., Dahlen, K., Loennechen, M., & Somogyi, A. (2006). ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clinical Pharmacology & Therapeutics, 80(6), 682-690. DOI Scopus128 WoS110 Europe PMC90
2006	Barratt, D., Coller, J., & Somogyi, A. (2006). Association between the DRD2 A(1) allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics. Part B: Neuropsychiatric Genetics, 141B(4), 323-331. DOI Scopus46 WoS43 Europe PMC39
2006	Barratt, D., Coller, J., & Somogyi, A. (2006). ABCB1 haplotypes determine methadone dosage requirements. ACTA PHARMACOLOGICA SINICA, 27, 229.

Book Chapters

Year	Citation
2022	Mustafa, S., Evans, S., Barry, B., Barratt, D., Wang, Y., Lin, C., . . . Hutchinson, M. R. (2022). Toll-Like Receptor 4 in Pain: Bridging Molecules-to-Cells-to-Systems.. In V. Kumar (Ed.), Toll-like Receptors in Health and Disease. Handbook of Experimental Pharmacology (Vol. 276, pp. 239-273). Springer Berlin Heidelberg. DOI Scopus2 Europe PMC2
2016	Coller, J., Barratt, D., & Somogyi, A. (2016). Clinically significant interactions with anti-addiction agents. In M. Jann, S. Penzak, & L. Cohen (Eds.), Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 565-577). Switzerland: Spinger. DOI

Conference Papers

Year	Citation
2016	Hu, R. (2016). CYP3A5*3 and ABCB1 haplotype 61A-1199G-1236T-2677T/A-3435T are associated with dose-adjusted trough blood tacrolimus concentration in kidney transplant recipients. In ASCEPT-MPGPCR 2016. Melbourne, Australia.

Conference Items

Year	Citation
2023	Hutchinson, M., Barratt, D. T., Holmes, J., Mustafa, S., Bajic, J. E., Kolarich, D., . . . Semmler, C. (2023). From blood markers to performance prediction: New insights for athletes and beyond. Poster session presented at the meeting of BRAIN BEHAVIOR AND IMMUNITY. CO, Boulder: ACADEMIC PRESS INC ELSEVIER SCIENCE. DOI

Dr Barratt teaches within the B.HlthMedSci program.

Current Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2022	Co-Supervisor	The Human Integrated Sensor System (HISS) Challenge	Doctor of Philosophy	Doctorate	Full Time	Mr Michail Laoumtzis
2021	Co-Supervisor	Regulation of the neuro-immune system	Doctor of Philosophy	Doctorate	Full Time	Mr Benjamin Daniel Barry

Past Higher Degree by Research Supervision (University of Adelaide)

Date	Role	Research Topic	Program	Degree Type	Student Load	Student Name
2019 - 2023	Co-Supervisor	Development and application of methods for pharmacokinetics (PK) analysis in PNG HIV/AIDS patients	Doctor of Philosophy	Doctorate	Full Time	Ms Natalia Bordin Andriguetti
2016 - 2019	Co-Supervisor	Genetics of Tacrolimus Pharmacokinetics and Kidney Transplant Outcomes	Doctor of Philosophy	Doctorate	Full Time	Ms Rong Hu
2014 - 2015	Co-Supervisor	Impact of CYP2C8 Single Nucleotide Polymorphisms on In-vitro Metabolism of Imatinib to N-desmethyl Imatinib	Master of Philosophy (Medical Science)	Master	Full Time	Mr Muhammad Suleman Khan

Committee Memberships

Date	Role	Committee	Institution	Country
2016 - ongoing	Member	Adelaide Medical School Health Safety and Welfare Committee	-	-
2013 - ongoing	Member	ASCEPT Scientific Advisory Committee	-	-
2013 - ongoing	Vice-Chair	ASCEPT Pharmacogenomics Special Interest Group	-	-

Memberships

Date	Role	Membership	Country
2020 - ongoing	Member	International Association for the Study of Pain	United States
2019 - ongoing	Member	Australasian Neuroscience Society	Australia
2005 - ongoing	Member	Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists	-

Position: Int Grant-Funded Researcher B
Phone: 83135985
Email: daniel.barratt@adelaide.edu.au
Campus: North Terrace
Building: Helen Mayo South, floor 5
Org Unit: Medical Sciences